Zhang, Haowen http://orcid.org/0000-0002-3513-4573
Song, Li
Wang, Xiaotao http://orcid.org/0000-0002-3531-2157
Cheng, Haoyu
Wang, Chenfei
Meyer, Clifford A.
Liu, Tao http://orcid.org/0000-0002-8818-8313
Tang, Ming http://orcid.org/0000-0002-7739-8913
Aluru, Srinivas http://orcid.org/0000-0003-4279-469X
Yue, Feng http://orcid.org/0000-0002-7954-5462
Liu, X. Shirley
Li, Heng http://orcid.org/0000-0003-4874-2874
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HG010040, R01HG011139, U01CA226196)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 10 June 2021
Accepted: 27 October 2021
First Online: 12 November 2021
Competing interests
: The authors declare the following competing interests. X.S.L. is a cofounder, board member, SAB member, and consultant of GV20 Oncotherapy and its subsidiaries; stockholder of BMY, TMO, WBA, ABT, ABBV, and JNJ; and received research funding from Takeda, Sanofi, Bristol Myers Squibb, and Novartis. H.L. is a consultant of Integrated DNA Technologies and on the SAB of Sentieon and Innozeen.